BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Rigel Initiates Phase 1 Clinical Trial of R835, an IRAK1/4 Inhibitor for Autoimmune and Inflammatory Diseases

  Rigel selected R835, a proprietary molecule from its interleukin receptor associated kinase (IRAK) preclinical development program, for human clinical trials.

  June 26, 2018

   · 

  4 min read
• Genetown

  Skyhawk Therapeutics Announces $40 Million Equity Investment Round

  Alongside its recently announced strategic collaboration, the Company has closed a new $40 million all-common stock equity investment by its strategic collaborators, major family investors, and leading venture funds

  June 26, 2018

   · 

  1 min read
• Business

  AbbVie and Calico Announce Extension of Groundbreaking Collaboration

  Extension builds on collaboration established in 2014

  June 26, 2018

   · 

  4 min read
• Business

  IsoPlexis Announces Research Collaboration with Nektar Therapeutics

  Program will Aim to Further Characterize the Functional Impact of Nektar Immunotherapies

  June 26, 2018

   · 

  3 min read
• Business

  National Alliance of Healthcare Purchaser Coalitions and Remedy Partners Collaborate to Accelerate Healthcare Payment Reform

  Integrated national platform aims to accelerate employer adoption of bundled payments

  June 26, 2018

   · 

  3 min read
• Genetown

  Aldeyra Therapeutics Announces Development Programs at 2018 Research Day

  Expanded Pipeline Features Distinct Mechanisms of Action Across Five Product Candidates

  June 26, 2018

   · 

  6 min read
• Business

  BioClin Therapeutics Appoints Scott Myers as Chairman to its Board of Directors

  BioClin Therapeutics, Inc., a privately-held clinical stage drug development company developing a first-in-class anti-FGFR3 (fibroblast growth factor receptor 3) monoclonal antibody in areas of high unmet medical need, announced today the appointment of Scott D. Myers as chairman of Board of Directors.

  June 26, 2018

   · 

  3 min read
• Reapplix- Positive Outcome Data of Large Randomized Controlled Trial Presented at American Diabetes Association Scientific Sessions

  Reapplix ApS announces that positive outcome data of an independent Randomized Controlled Trial (RCT) of its LeucoPatch® wound healing platform was presented at the American Diabetes Association 78th Scientific Sessions meeting.

  June 26, 2018

   · 

  5 min read
• BioMidwest

  Bio-Techne Expands RNAscope® Assay Services Portfolio to Shorten Development Times and Save Costs

  Validated tissue bank and pre-collected immuno-oncology datasets speed up investigative research projects through to clinical development...

  June 26, 2018

   · 

  4 min read
• Biotech Beach

  Cibus Raises $70M in Series C Funding

  Cibus, a leader in the application of gene editing technologies for directed mutagenesis, announced it has raised $70 million in a Series C funding.

  June 26, 2018

   · 

  2 min read